GleamWall
中文EN

NNVC NANOVIRICIDES, INC.

Pharmaceutical Preparations · NYSE · SEC CIK 1379006 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-49.9%
TTM EPS YoY-8.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-179.2%
ROA-135.9%
ROIC (approx.)-196.2%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets33.5%
Debt / equity0.00x
Current ratio0.95x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-27.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-09-302026Q4*2026-06-302026Q3*2026-03-312026Q2*2025-12-312026Q12025-09-302025Q4*2025-06-302025Q3*2025-03-312025Q2*2024-12-31
Income statement
Revenue$0$0$0$0$0$0$0$0
R&D expense$4.70M$1.31M$1.29M$1.12M$993,066$1.18M$1.28M$1.16M
SG&A expense$1.07M$936,316$744,276$1.11M$803,619$938,195$966,905$902,700
Operating income-$5.77M-$2.25M-$2.03M-$2.23M-$1.80M-$2.12M-$2.25M-$2.06M
Interest expense—————$0$0$149
Net income-$5.74M-$2.22M-$1.99M-$2.22M-$1.79M-$2.10M-$2.22M-$2.03M
EBITDA-$5.64M-$2.12M-$1.90M-$2.10M-$1.67M-$1.96M-$2.06M-$1.87M
EPS (basic)-0.23—-0.09-0.11-0.10—-0.14-0.14
EPS (diluted)-0.23—-0.09-0.11-0.10—-0.14-0.14
Weighted avg. shares (diluted)24.79M—21.61M19.85M17.08M—16.03M14.57M
Balance sheet
Cash & equivalents$2.58M$2.79M$3.21M$5.15M$1.13M$1.56M$2.54M$3.96M
Current assets$2.98M$3.16M$3.38M$5.30M$1.25M$1.67M$2.73M$4.07M
PP&E, net$6.28M$6.40M$6.53M$6.66M$6.79M$6.83M$6.98M$7.17M
Intangibles$306,701$308,769$310,836$312,904$314,971$317,039$319,106$321,174
Total assets$9.56M$9.87M$10.22M$12.27M$8.36M$8.82M$10.03M$11.57M
Current liabilities$3.15M$1.19M$1.07M$1.20M$1.18M$1.31M$1.20M$1.18M
Total liabilities$3.20M$1.20M$1.10M$1.20M$1.20M$1.30M$1.20M$1.20M
Shareholders' equity$6.41M$8.68M$9.15M$11.07M$7.17M$7.52M$8.83M$10.39M
Shares outstanding25.55M23.01M21.65M21.60M17.56M16.61M16.07M15.64M
Cash flow statement
Operating cash flow-$3.64M-$2.12M-$1.93M-$2.05M-$1.59M-$1.70M-$1.99M-$2.19M
Capital expenditure—$1$0-$1$84,317$10,200$0$0
Free cash flow—-$2.12M-$1.93M-$2.05M-$1.68M-$1.71M-$1.99M-$2.19M
Investing cash flow—-$1$0$1-$84,317-$10,200$0$0
Financing cash flow$3.42M$1.70M-$6,742$6.07M$1.25M$728,080$575,503$2.28M
Depreciation & amortization$126,123$127,682$127,566$131,016$130,752$159,059$189,114$193,816

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.